These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 657163)

  • 1. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice.
    Pacciarini MA; Barbieri B; Colombo T; Broggini M; Garattini S; Donelli MG
    Cancer Treat Rep; 1978 May; 62(5):791-800. PubMed ID: 657163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.
    Broggini M; Italia C; Colombo T; Marmonti L; Donelli MG
    Cancer Treat Rep; 1984 May; 68(5):739-47. PubMed ID: 6586294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.
    Charrois GJ; Allen TM
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice.
    Broggini M; Colombo T; D'Incalci M
    Cancer Treat Rep; 1983 Jun; 67(6):555-9. PubMed ID: 6861161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-Epi-doxorubicin and hyperthermia in a murine mammary carcinoma: influence of the dose and fractionation.
    Cividalli A; Danesi DT; Altavista P; Bonanni M; Persiani D; Segre L; Cruciani G
    Anticancer Res; 1995; 15(3):739-43. PubMed ID: 7645951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
    Israel M; Modest EJ; Frei E
    Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between heparin and adriamycin in mice bearing the Lewis lung carcinoma.
    Colombo T; Delaini F; Ferrari R; Donati MB; Donelli MG; Poggi A
    Biomedicine; 1981 Dec; 34(3):124-8. PubMed ID: 7337798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
    Leto G; Tumminello FM; Gebbia N; Woynarowska B; Bernacki RJ
    Anticancer Res; 1990; 10(1):265-9. PubMed ID: 2334138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice.
    Bibby DC; Talmadge JE; Dalal MK; Kurz SG; Chytil KM; Barry SE; Shand DG; Steiert M
    Int J Pharm; 2005 Apr; 293(1-2):281-90. PubMed ID: 15778066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of para-Chloroaniline Hydrochloride (CAS No. 20265-96-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1989 Jul; 351():1-256. PubMed ID: 12704433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.